Biotech Week articles from November 2004

Biotech Week archives from November 2004

Phase III trial update provided on Bio-E-Gel.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Antares Pharma, Inc., (AIS), an evolving specialty pharmaceutical company with headquarters in Exton, Pennsylvania, announced an update regarding the ongoing pivotal phase III clinical trial of its...

Promising validation results for ovarian cancer biomarkers presented at meeting.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Ciphergen Diagnostics, a division of Ciphergen Biosystems, Inc., (CIPH), presented initial results of its ongoing study to validate biomarkers for ovarian cancer and reported progress in assay...

FDA approves medical device to treat AAA.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Cook, Inc., a privately held medical-device manufacturer, announced that the U.S. Food and Drug Administration (FDA) has approved the company's next-generation solution for abdominal aortic aneurysms...

Company reports positive phase IIa trial results in postsurgical pain.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- DELEX Therapeutics, a privately held specialty pharmaceutical company, presented a preview of its phase IIa clinical trial results with its lead product AeroLEF (aerosolized liposome encapsulated...

U.S. FDA grants Fast Track designation for FK228 in cutaneous T cell lymphoma.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Gloucester Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for FK228 (depsipeptide) as monotherapy for the treatment of cutaneous T...

FDA gives final approval for Brimonidine Tartrate Ophthalmic Solution, 0.2% ANDA.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- IVAX Corporation (IVX) has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for brimonidine tartrate ophthalmic solution, 0.2%....

3F Aortic Bioprosthesis heart valve gets CE mark of conformity.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- 3F Therapeutics, Inc., announced that the 3F Aortic Bioprosthesis Model 1000 has received CE Marking of Conformity (CE 0123) in accordance with the European Medical Device Directive. Obtaining the...

Maryland adopts classification system for payment of healthcare services.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- 3M Health Information Systems Division announced that the Maryland Health Services Cost Review Commission (HSCRC) has selected its 3M APR-DRG classification system as the State of Maryland's methodology...

PC cell-derived growth factor inflames breast tumor aggression.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- PC cell-derived growth factor inflames breast tumor aggression. According to recent research published in the journal Carcinogenesis, "metastasis is a multi-step process involved in the progression...

Statistically significant positive phase II data reported on Cetrorelix.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- AEterna Zentaris, Inc., (AEZ; AEZS) announced statistically significant positive results from a randomized, double-blind, placebo-controlled phase II trial designed to evaluate different dosage regimens...

Biotech company representative testified about proposal for BioShield II.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- AVI BioPharma, Inc., (AVII) announced that Alan P. Timmins, AVI's president and COO, testified in a joint hearing before the U.S. Senate Committee on Health, Education, Labor and Pensions and the U.S....

RANTES haplotypes influence the response to chronic hepatitis C therapy.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- RANTES haplotypes influence the response to chronic hepatitis C therapy. "The response to antiviral therapy for chronic hepatitis C virus (HCV) is complex and is determined by both environmental and...

Esophagus shear modulus of elasticity studied in rat model.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Esophagus shear modulus of elasticity has been studied in a rat model. "Experimental and diagnostic procedures like distension of a balloon catheter, bougie, and esophagogastroduodenoscopy can...

Alcohol consumption may be associated with irregular heartbeat in men.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Alcohol consumption may slightly increase the risk for developing a certain type of irregular heart beat, known as atrial fibrillation, or atrial flutter, according to new research. Evidence for a...

Novel antiapoptotic protein X-linked IAP antagonists potential cancer therapy.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Novel antiapoptotic protein XIAP antagonists are a potential therapy for cancers overexpressing X-linked IAP. "Inhibitor of apoptosis (IAP) proteins are overexpressed in many cancers and have been...

Architect Systems' fertility menu enhanced with test for Estradiol.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories announced an enhanced fertility menu for its Architect family of analyzers with the introduction of an improved Architect Estradiol test. Offering excellent clinical performance,...

Positive trial results reported for ABX10241 antibody product candidate.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Abgenix, Inc., (ABGX) announced positive results from an ongoing phase I clinical trial of ABX10241 (ABX-PTH), the company's fully human monoclonal antibody that targets parathyroid hormone (PTH). ...

FDA fast track status granted for modified vaccinia ankara program.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Acambis plc (ACM, ACAM) announced that its joint project with Baxter Healthcare SA to develop a Modified Vaccinia Ankara (MVA) vaccine has been designated as a "fast track" development program by the...

U.S. HHS awards $232 million in biodefense contracts for vaccine development.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- U.S. Health and Human Services (HHS) Secretary Tommy G. Thompson announced 4 new contracts totaling more than $232 million to fund development of new vaccines against 3 potential agents of bioterrorism:...

Chemical compound catalogs added to cheminformatics database.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Accelrys, Inc., (ACCL) announced an agreement to integrate the Sigma-Aldrich (SIAL) chemical compound catalogs into Accelrys' chemical suppliers database, Chemicals Available for Purchase (CAP). ...

Results from phase I trial of AP5346 presented at meeting in Switzerland.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Access Pharmaceuticals, Inc., (AKC) announced that the results from the phase I clinical trial of AP5346 a DACH Platinum Polymer Therapeutic were presented on October 1, 2004, at the 16th EORTC-NCI-AACR...

eTag technology evaluated for patient selection for targeted cancer therapies.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Aclara BioSciences (ACLA) announced that they have entered into an agreement with GlaxoSmithKline (GSK) to evaluate Aclara's proprietary eTag technology assays for their potential use in patient...

In vivo results presented on AC-100.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Acologix, Inc., a privately held biopharmaceutical company, presented data from in vivo preclinical studies of its lead compound, AC-100, during the 26th Annual Meeting of the American Society for Bone...

Pharmaceutical firm receives grant from NIH for diarrhea drug development.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Active Pass Pharmaceuticals announced receipt of a grant of CDN $3.6 million for development of a novel treatment for secretory diarrhea. The award was made by the National Institute of Allergy and...

Drug firm closes $15M financing, initiates trial of RNAi therapeutic.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Acuity Pharmaceuticals, a product-focused ophthalmic pharmaceutical company, announced the closing of a $15 million Series B financing. Acuity also announced it has initiated a phase I clinical...

Pharmaceutical company leapfrogs from seed funding to major milestones.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, congratulated its portfolio company Acuity Pharmaceuticals on the closing of its $15 million series B financing and the initiation...

Peptide-HSP70 complexes generate cytolytic T-lymphocyte responses.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Peptides complexed with the protein HSP70 generate efficient human cytolytic T-lymphocyte responses. According to recent research published in the journal Biochemical Society Transactions,...

Patent issued for method of improving drug delivery to tumors.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Adherex Technologies, Inc., (AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, announced that it has been issued U.S. Patent No. 6,797,807, entitled...

Device firm withdraws $22 per share Cyberonics proposal.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Advanced Neuromodulation Systems, Inc., (ANS, ANSI) announced that it has withdrawn its proposal to discuss a combination with Cyberonics, Inc., (CYBX) in which ANS was prepared to offer $22.00 per...

Nutraceuticals company reports release of escrow funds.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Advanced Nutraceuticals, Inc., (ANII) announced that it has received the $250,000 proceeds, with no deduction, from the escrow account that had been established in connection with the March 2004 sale of...

CoFactor results reported showing antitumor activity, lower systemic toxicity.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Adventrx Pharmaceuticals, Inc., (ANX) announced the results of recent preclinical studies demonstrating enhanced antitumor activity with lower systemic toxicity in a mouse model for colorectal cancer...

Device companies announce distribution agreement for nebulizer system.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Aerogen, Inc., (AEGN) and Respironics, Inc., (RESP) announced that they have entered into a worldwide, non-exclusive distribution agreement for Aerogen's Aeroneb Professional Nebulizer System (Aeroneb...

Phase I trial of Hematide initiated.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Affymax, Inc., announced that it has initiated a placebo controlled, phase I dose-finding clinical trial with its lead product candidate, Hematide, a peptide-based erythropoiesis stimulating agent (ESA)...

Clinical investigators review, endorse phase 2 trials for deep vein therapy.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Agenix Limited [AGXLY] announced that clinical investigators to be involved in its phase 2 ThromboView deep vein thrombosis (DVT) clinical trial have met, reviewed and endorsed all aspects of the trial....

More than 1 million Bioanalyzer chips sold.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Agilent Technologies, Inc., (A) announced that it has sold more than one million LabChip chips - small, analytical devices used with the Agilent 2100 bioanalyzer to perform fast, automated analysis of...

Cyclooxygenase-2 is target for disorders of skin and oral cavity.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. According to a study from Japan, "Anti-cancer...

A new magnetic extraction method uncovers HCV status in hemodialysis patients.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- A new magnetic extraction method uncovers HCV status in hemodialysis patients. According to recent research from Japan, "hemodialysis patients are a high-risk group for hepatitis C virus (HCV)...

Agreement signed with Cardinal Health for distribution of tests.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Akers Biosciences, Inc., (AKR) announced that it has signed an agreement with Cardinal Health to distribute Akers' rapid diagnostic tests to U.S. healthcare markets. Cardinal Health will initially...

Heat shock protein is cytoprotective in gastric mucosa of cirrhosis.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Expression of a 72-kDa heat shock protein is cytoprotective in the gastric mucosa of cirrhotic rats. Portal hypertensive gastropathy (PHG) is a clinical entity that is observed frequently in...

Milestone achieved in home dialysis.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Aksys, Ltd., (AKSY), developer of hemodialysis products and services for patients suffering kidney failure has announced that in September the company passed the significant milestone of 100 patients...

Pharmaceutical company divests its Resins business.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Akzo Nobel has signed an agreement to sell its Ultra Violet/ Electron Beam (UV/EB) Resins business to Cray Valley S.A. of France (part of the Total Group). Sales of the business were EUR 27 million...

3-D fusion imaging is useful in decisions about coronary artery disease.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- A recent study evaluated 3-D integration of myocardial scintigraphic data of patients with ischemic cardiomyopathy. Researchers in Germany conducted a study "to determine the prevalence of viable...

Pharmaceutical company raises GBP 16M, seeks admission to AIM.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Allergy Therapeutics, a pharmaceuticals company focused on allergy vaccines, announced that it has successfully placed 21,917,808 new ordinary shares at 73 pence per share, conditional on its admission...

Imaging company promotes Andrew Hayek to president, COO.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Alliance Imaging, Inc., (AIQ), a national provider of diagnostic imaging solutions, announced the promotion of Andrew Hayek to president in addition to his role as chief operating officer. In his...

Multiyear agreement renewed for reprocessing services.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Alliance Medical Corporation (Alliance), a reprocessor of single-use medical devices (SUDs), announced that Mayo Foundation has extended its agreement with Alliance for medical device reprocessing...

Update provided on revised Oxygent development plan.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Alliance Pharmaceutical Corp. (ALLP) announced that it has received clarification from the European Agency for the Evaluation of Medical Products (EMEA) regarding development recommendations for Oxygent...

Brain metastases patients' radiographic response at 3 months predicts survival.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- For brain metastases patients undergoing whole brain radiation therapy (WBRT), radiographic response in the brain at 3 months is a statistically significant predictor of prolonged survival, according to...

New findings from EFAPROXYN brain metastases trial releases.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (NASDAQ:ALTH) announced the presentation of new findings from its phase 3 clinical trial of the investigational radiation sensitizer EFAPROXYN (efaproxiral) in patients with...

Pharmaceutical company announces third quarter 2004 trading update.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Alltracel Pharmaceuticals PLC (AP.L) announced strong third quarter revenues of EUR 0.7M, bringing the year to date cumulative revenues to EUR 2.7M versus EUR 0.6M for the same period of 2003. In...

FDA approval granted for Metformin Hydrochloride 500 mg.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Alpharma, Inc., (ALO) announced that Purepac Pharmaceutical Co., a subsidiary of Alpharma, has received final approval from the U.S. Food and Drug Administration (FDA) for metformin hydrochloride...

Neuroscience company raises $12.75M in private placement.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Amarin Corporation plc (AMRN) announced that it has completed a private placement of 13,448,546 ordinary shares to a group of new and existing accredited investors and management, raising gross proceeds...

Study: Anti-dust mite covers effective in reducing allergens.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- A new study provides evidence that people who have allergic asthma and use dust mite-impermeable bed covers have improved peak flow measurements. These findings are featured in the October 2004...

Allergy academy presents Samter Journalism Awards for health, medical reporting.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- The American Academy of Allergy, Asthma and Immunology (AAAAI) announced the 5th Annual Samter Journalism Award Program. The AAAAI developed the Samter Award to celebrate and award outstanding...

Pediatricians: Flu vaccine needed to protect children under age 2.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- In a written statement submitted for a U.S. House of Representatives hearing, the American Academy of Pediatrics (AAP) reiterated the need for children ages 6-23 months to get vaccinated with the flu...

Chinese biotech firm appoints independent director of company.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- American Oriental Bioengineering, Inc., (AOBO) announced the appointment of Cosimo J. Patti as an independent director of the company. Patti brings more than 30 years of experience in international...

Pharmaceutical company announces addition of three executives.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- American Pharmaceutical Partners, Inc., (APPX) announced that it has appointed three new senior executives, all with considerable big pharma experience, to the operating senior management team. ...

APA applauds passage of Mentally Ill Offender Treatment and Crime Reduction Act.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- The American Psychological Association (APA) applauded the U.S. House of Representatives for passing S. 1194, the Mentally Ill Offender Treatment and Crime Reduction Act of 2004. Sponsored by Sen....

Actor brought strength, larger-than-life clout to spinal cord research.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- By the time he died, Christopher Reeve had at last "escaped the cape," he had become bigger than the Superman character he portrayed on screen. Reeve championed cutting-edge research into spinal...

CTLA4 may be a susceptibility gene for type 1 diabetes.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- CTLA4 may be a susceptibility gene for type 1 diabetes. "Type 1 diabetes (T1D) is a complex autoimmune disease. Several genetic loci have been implicated in the susceptibility to this illness....

Pharmaceutical services company projects earnings per share.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- AmerisourceBergen Corporation (ABC) announced that due to lower than anticipated pharmaceutical price increases in the September quarter of 2004, it expects earnings per diluted share for the fiscal...

U.S. FDA approves new and easy way to take ENBREL.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Amgen, Inc., (AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (WYE), announced that the new 50 mg/mL prefilled syringe of Enbrel (etanercept) has been approved by the U.S. Food and Drug...

HIV-1 gp120-induced nitric oxide increases proinflammatory cytokines.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- HIV-1 gp120-induced nitric oxide increases proinflammatory cytokines. "It has become clear that spinal cord glia (microglia and astrocytes) importantly contribute to the creation of exaggerated pain...

Investigational therapy for bone loss increased bone mineral density.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Amgen, Inc., (AMGN) announced that at all doses studied, twice yearly injections of AMG 162, the company's investigational therapy for bone loss, significantly increased bone mineral density (BMD) at...

Health plan completes migration to payer software application.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Prevea Health Plan has successfully implemented Release 1 of the AMISYS Advance payer software system, an enterprise-wide, robust application from Amisys Synertech Inc. that assists health plans with...

Pharmaceuticals firm announces executive promotions in R&D.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Anadys Pharmaceuticals, Inc., (ANDS) announced two executive promotions. Steve Worland, PhD, former chief scientific officer, has been promoted to executive VP, head of research and development, and...

Biotech company undertakes value-enhancement plan.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Andromed, Inc., (AD) reported a value enhancement and restructuring plan aimed at rapidly raising Andromed's technological and strategic value with a view to a transaction leading to the merger or the...

Medical device firm reports first quarter sales up 23%.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- AngioDynamics, Inc., (ANGO) announced financial results for the 13 weeks ended August 28, 2004. Net sales of $13.1 million for the fiscal year 2005 first quarter increased 23% compared with net...

Thirty-day safety data reported from Taxus V drug-eluting stent clinical trial.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Angiotech Pharmaceuticals, Inc., (ANPI, ANP) corporate partner, Boston Scientific, announced 30-day safety data from its Taxus V clinical trial. The trial is assessing the slow-release formulation...

Pharmaceutical company adds new business development executive.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Anika Therapeutics, Inc., (ANIK) announced the appointment of Elizabeth C. Chen as senior vice president of marketing and business development, a newly created executive position. Chen will be...

Sweet broomweed possesses antidiabetic activity.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- The traditional antidiabetic plant Scoparia dulcis (sweet broomweed) was cytoprotective in a rat insulinoma cell line. "Scoparia dulcis (sweet broomweed) has been documented as a traditional...

Biotech firm to establish Level 1 American Depository Receipt program.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Antisense Therapeutics Limited announced that it has accepted a proposal from The Bank of New York to establish a Level 1 American Depository Receipt (ADR) program. The establishment of this ADR...

Court dismisses Promega's case against Applied Biosystems and Roche.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Applied Biosystems (ABI), an Applera Corp. business, announced that the U.S. District Court in Alexandria, Virginia, has dismissed on multiple grounds a case filed by the Promega Corp. against Applied...

p-tau 231 assay improves early stage Alzheimer disease detection.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- An assay developed by Applied NeuroSolutions (APNS), when combined with magnetic resonance imaging (MRI), was shown to identify neural signposts in patients with mild cognitive impairment (MCI), a...

Merger creates discovery services, respiratory drug development firm.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Argenta Discovery, Ltd., and Etiologics, Ltd., announced that they have merged to create a powerful new firm that provides comprehensive drug discovery contract research capabilities to global...

Device company appoints Frank Husic to board of directors.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Argonaut Technologies, Inc., (AGNT) announced the appointment of Frank Husic to the Argonaut Technologies board of directors. Including Husic, the Argonaut Technologies board of directors will now...

Company changes name and prepares for HIV vaccine trial.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Research company Merix Bioscience announced the change of its name to Argos Therapeutics, Inc. Additionally, the company stated that it is preparing for an HIV clinical trial with Argos' proprietary...

Tumor regression reported with AP23573 in relapsed, refractory cancer.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Ariad Pharmaceuticals, Inc., (ARIA) announced, for the first time, updated results of two phase I clinical trials of its novel mTOR inhibitor, AP23573 as a single agent, showing documented tumor...

Device company acquires U.K.-based distributor Actamed.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Arizant announced the purchase of the company's United Kingdom-based distributor, Actamed, Ltd., In 2002, the company, through its international subsidiary, acquired a 25% interest in the distributor...

Biotech company appoints senior director of drug metabolism.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Array BioPharma, Inc., (ARRY) announced the appointment of Ronald B. Franklin, PhD, DABT, to the newly created position of senior director of drug metabolism, effective September 27, 2004. Franklin...

Cooperation, license agreements signed related to mouse genetics.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Artemis Pharmaceuticals GmbH (Cologne) and Boehringer Ingelheim (Ingelheim, Germany and Ridgefield, Connecticut) have signed service and license agreements in the area of mouse genetics and genomics....

JCAHO Sentinel Event Alert issued targeted at preventing anesthesia awareness.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Aspect Medical Systems (ASPM) announced that the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) has issued a new Sentinel Event Alert (issue no. 32) aimed at preventing and...

Device firm estimates fiscal 2005 financial results.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Aspen Technology, Inc., (AZPN) announced that based upon preliminary data, it expects to report, under generally accepted accounting principles in the United States or GAAP, total revenues of...

Biotech firm appoints David Welch to the board of directors.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- AspenBio, Inc., (APNB) announced that David Welch has been appointed to the board of directors. Welch has also been elected as chairman of the company's audit committee and will serve as a member...

Tezosentan at 1-25 mg/h improves hemodynamics and reduces B natriuretic peptide.
November 3, 2004... 2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Recent research investigated the hemodynamic and neurohonnonal effects of low doses of tezosentan, an endothelin A/B receptor antagonist, in patients with acute heart failure. Scientists from...